Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Cell Structure Alteration”

43 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 43 results

Testing effectiveness (Phase 2)Study completedNCT03037385
What this trial is testing

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Who this might be right for
RET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+37 more
Hoffmann-La Roche 590
Testing effectiveness (Phase 2)Active Not RecruitingNCT04280081
What this trial is testing

Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

Who this might be right for
Solid TumorMedullary Thyroid Cancer
Eli Lilly and Company 77
Not applicableStudy completedNCT06173128
What this trial is testing

Respiratory Microbiota and Immune Response in CVID

Who this might be right for
CVID
Boston University 75
Large-scale testing (Phase 3)Ended earlyNCT04222972
What this trial is testing

Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
RET-fusion Non Small Cell Lung CancerLung NeoplasmCarcinoma, Non-Small-Cell Lung+14 more
Hoffmann-La Roche 223
Early research (Phase 1)Study completedNCT01742286
What this trial is testing

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Who this might be right for
ALK-activated Tumors
Novartis Pharmaceuticals 83
Testing effectiveness (Phase 2)Ended earlyNCT04161391
What this trial is testing

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Who this might be right for
Non Small Cell Lung CancerMedullary Thyroid CancerRET Gene Mutation+2 more
Turning Point Therapeutics, Inc. 41
Not applicableUnknownNCT04425798
What this trial is testing

Connectivity Alterations After Levetiracetam Application

Who this might be right for
GliomaEpilepsy
Beijing Neurosurgical Institute 30
Testing effectiveness (Phase 2)Study completedNCT01149863
What this trial is testing

Alteration in Timing of Plerixafor Administration

Who this might be right for
Autologous Transplantation
Emory University 34
Testing effectiveness (Phase 2)UnknownNCT03925350
What this trial is testing

Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation

Who this might be right for
Metastatic Melanoma
California Pacific Medical Center Research Institute 41
Large-scale testing (Phase 3)Looking for participantsNCT07218380
What this trial is testing

Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Who this might be right for
Carcinoma, Transitional CellUrinary Bladder NeoplasmsNeoplasm Metastasis
Eli Lilly and Company 450
Testing effectiveness (Phase 2)Looking for participantsNCT06239272
What this trial is testing

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Who this might be right for
Adipocytic NeoplasmLiposarcomaAtypical Fibroxanthoma+6 more
St. Jude Children's Research Hospital 139
Early research (Phase 1)Study completedNCT03817125
What this trial is testing

Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention

Who this might be right for
Metastatic Melanoma
Parker Institute for Cancer Immunotherapy 14
Testing effectiveness (Phase 2)Looking for participantsNCT06669117
What this trial is testing

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

Who this might be right for
Solid TumorMET Alteration
Pierre Fabre Medicament 140
Post-approval studies (Phase 4)Looking for participantsNCT06820255
What this trial is testing

DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.

Who this might be right for
Bladder (Urothelial, Transitional Cell) Cancer Metastatic or UnresectableUpper Tract Urothelial Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 135
Not applicableLooking for participantsNCT04623424
What this trial is testing

Intestinal Microbiota in Stem Cell Transplant Transplant Admission

Who this might be right for
Stem Cell Transplant Complications
Henry Ford Health System 255
Testing effectiveness (Phase 2)Looking for participantsNCT05020912
What this trial is testing

Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy

Who this might be right for
Basal Cell Carcinoma
Case Comprehensive Cancer Center 28
Testing effectiveness (Phase 2)Looking for participantsNCT04040205
What this trial is testing

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

Who this might be right for
ChondrosarcomaOsteosarcomaSoft Tissue Sarcoma
Medical College of Wisconsin 44
Early research (Phase 1)Ended earlyNCT05242822
What this trial is testing

Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Who this might be right for
Solid Tumor, AdultIntrahepatic CholangiocarcinomaUrothelial Carcinoma
Kinnate Biopharma 54
Not applicableUnknownNCT03509779
What this trial is testing

Pronostic and Predictive Value of EMT in Localized Lung Cancer

Who this might be right for
NSCLC, Stage I, II, IIIA, IIIBSurgeryProgression+1 more
European Georges Pompidou Hospital 1,000
Testing effectiveness (Phase 2)Study completedNCT05253807
What this trial is testing

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Incyte Corporation 8
Load More Results